VCBeat Health
Contact Us
Home
China Healthcare Select
Insights
MNC China Lens
Vertical Industries
Services
Partnership Development
Market Entry Advisory
Ecosystem Engagement Advisory
About VCBeat
Why VCBeat
Log In
Home
Dual-Target CD19/BCMA CAR-T Therapy Demonstrates Sustained Remission in Refractory Systemic Sclerosis
Dual-Target CD19/BCMA CAR-T Therapy Demonstrates Sustained Remission in Refractory Systemic Sclerosis
Jun 08, 2026 22:59 CST Updated Jun 09, 02:26
Share:
